Kuros Biosciences Liabilities 2024

Kuros Biosciences Aktienanalyse

What does Kuros Biosciences do?

Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Kuros Biosciences's Liabilities

Kuros Biosciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Kuros Biosciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Kuros Biosciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Kuros Biosciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Kuros Biosciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Kuros Biosciences Stock

What is the level of liabilities of Kuros Biosciences this year?

Kuros Biosciences has a debt balance of 14.75 M CHF this year.

What were the liabilities of Kuros Biosciences compared to the previous year?

The liabilities of Kuros Biosciences have increased by 4.73% increased compared to the previous year.

What are the consequences of high debt for investors of Kuros Biosciences?

High liabilities can pose a risk for investors of Kuros Biosciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Kuros Biosciences?

Low liabilities mean that Kuros Biosciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Kuros Biosciences affect the company?

An increase in liabilities of Kuros Biosciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Kuros Biosciences affect the company?

A decrease in the liabilities of Kuros Biosciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Kuros Biosciences?

Some factors that can influence the liabilities of Kuros Biosciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Kuros Biosciences so important for investors?

The liabilities of Kuros Biosciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Kuros Biosciences take to modify the liabilities?

To change its liabilities, Kuros Biosciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Kuros Biosciences pay?

Over the past 12 months, Kuros Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kuros Biosciences is expected to pay a dividend of 0 CHF.

What is the dividend yield of Kuros Biosciences?

The current dividend yield of Kuros Biosciences is .

When does Kuros Biosciences pay dividends?

Kuros Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kuros Biosciences?

Kuros Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kuros Biosciences?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kuros Biosciences located?

Kuros Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kuros Biosciences from 6/7/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.

When did Kuros Biosciences pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Kuros Biosciences in the year 2023?

In the year 2023, Kuros Biosciences distributed 0 CHF as dividends.

In which currency does Kuros Biosciences pay out the dividend?

The dividends of Kuros Biosciences are distributed in CHF.